Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

BACKGROUND: Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Ressler, Julia Maria, Karasek, Matthias, Koch, Lukas, Silmbrod, Rita, Mangana, Joanna, Latifyan, Sofiya, Aedo-Lopez, Veronica, Kehrer, Helmut, Weihsengruber, Felix, Koelblinger, Peter, Posch, Christian, Kofler, Julian, Michielin, Olivier, Richtig, Erika, Hafner, Christine, Hoeller, Christoph
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2021
Schlagworte:
Oncolytic and Local Immunotherapy
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7898852/
https://ncbi.nlm.nih.gov/pubmed/33608376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001701
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge